U.S., Aug. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07140666) titled 'Analysis of Infuence Factors on Osteopenia in Different Treatment of Psoriasis' on Aug. 22.

Brief Summary: This clinical study aims to evaluate and compare changes in bone mineral density (BMD) and bone metabolism markers in patients with moderate-to-severe psoriasis treated with either Secukinumab or Adalimumab. Psoriasis is a chronic inflammatory disease that may increase the risk of osteoporosis. While biological therapies have shown efficacy in controlling skin lesions, their long-term effects on bone health remain unclear. By assessing lumbar spine and hip BMD and relevant biomarkers over time, this study seeks to clarify the b...